Correspondence 0001193125-24-033117 from Q32 Bio Inc. (QTTB)
Q32 Bio Inc.
Date: Feb. 13, 2024 · CIK: 0001661998 · Accession: 0001193125-24-033117
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276093
Letter
Homology Medicines, Inc.
One Patriots Park
Bedford, MA
February 13, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Re:
Homology Medicines, Inc.
Registration Statement on Form S-4
Originally Filed December 18, 2023
(File No. 333-276093)
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the above-referenced Registration Statement on Form S-4 so that it will become effective as of 2:00 p.m., Eastern Time, on February 14, 2024, or as soon thereafter as practicable, or at such later time as Homology Medicines, Inc. (the “Company”) or its counsel may request via telephone call to the Staff. Please contact Elisabeth M. Martin of Latham & Watkins LLP at (617) 948-6018 to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Sincerely yours,
Homology Medicines, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Homology Medicines, Inc. One Patriots Park Bedford, MA 01730 February 13, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Homology Medicines, Inc. Registration Statement on Form S-4 Originally Filed December 18, 2023 (File No. 333-276093) Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the above-referenced Registration Statement on Form S-4 so that it will become effective as of 2:00 p.m., Eastern Time, on February 14, 2024, or as soon thereafter as practicable, or at such later time as Homology Medicines, Inc. (the “Company”) or its counsel may request via telephone call to the Staff. Please contact Elisabeth M. Martin of Latham & Watkins LLP at (617) 948-6018 to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter. Sincerely yours, Homology Medicines, Inc. By: /s/ Paul Alloway, Ph.D. Name: Paul Alloway, Ph.D. Title: President and Chief Operating Officer cc: Elisabeth M. Martin, Esq., Latham & Watkins LLP Peter N. Handrinos, Esq., Latham & Watkins LLP Leah R. Sauter, Esq., Latham & Watkins LLP